Endometriosis Imaging Study Published in The Lancet Obstetrics, Gynaecology & Women’s Health Highlights ⁹⁹ᵐTc-maraciclatide as a Promising Diagnostic and Monitoring Tool

Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ^99mTc-maraciclatide, and the Nuffield Department of Women’s & Reproductive Health at the University of Oxford announce the journal publication of Phase 2 data from the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) imaging study. The paper, published open access online in The Lancet Obstetrics, Gynaecology & Women’s Health, highlights that ^99mTc-maraciclatide has potential as…